OpenLB
Open Library of Bioscience
Advanced Search
Cannabis and cannabinoid research
2017;2 (1): 48-60.

Cannabinoid CB and CB Receptor Signaling and Bias.

Mikkel Søes Ibsen, Mark Connor, Michelle Glass
Author Information
  1. Mikkel Søes Ibsen: Department of Pharmacology, School of Medical Sciences, University of Auckland, Auckland, New Zealand.
  2. Mark Connor: Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, 2 Technology Place, Macquarie University, New South Wales, Australia.
  3. Michelle Glass: Department of Pharmacology, School of Medical Sciences, University of Auckland, Auckland, New Zealand.
PMID: 28861504 DOI: 10.1089/can.2016.0037

Abstract

An agonist that acts through a single receptor can activate numerous signaling pathways. Recent studies have suggested that different ligands can differentially activate these pathways by stabilizing a limited range of receptor conformations, which in turn preferentially drive different downstream signaling cascades. This concept, termed "biased signaling" represents an exciting therapeutic opportunity to target specific pathways that elicit only desired effects, while avoiding undesired effects mediated by different signaling cascades. The cannabinoid receptors CB and CB each activate multiple pathways, and evidence is emerging for bias within these pathways. This review will summarize the current evidence for biased signaling through cannabinoid receptor subtypes CB and CB.

Keywords

G protein-coupled receptor agonist bias cannabinoid receptors functional selectivity

References

  1. Mol Pharmacol. 2016 Mar;89(3):364-75 [PMID: 26700564]
  2. Pharmacol Biochem Behav. 1991 Nov;40(3):565-9 [PMID: 1806946]
  3. J Neurosci. 2003 Mar 15;23(6):2371-82 [PMID: 12657697]
  4. Mol Pharmacol. 2012 Feb;81(2):250-63 [PMID: 22064678]
  5. J Mol Endocrinol. 2015 Feb;54(1):75-89 [PMID: 25510402]
  6. J Pharmacol Exp Ther. 1997 Sep;282(3):1632-42 [PMID: 9316881]
  7. Br J Pharmacol. 2015 Jan;172(2):492-500 [PMID: 24597632]
  8. Mov Disord. 2003 Feb;18(2):138-49 [PMID: 12539206]
  9. Br J Pharmacol. 2016 Jan;173(1):115-27 [PMID: 26398720]
  10. Proc Natl Acad Sci U S A. 2005 Dec 27;102(52):19144-9 [PMID: 16365309]
  11. Science. 2002 May 31;296(5573):1636-9 [PMID: 12040175]
  12. Br J Pharmacol. 1992 Jun;106(2):231-2 [PMID: 1327374]
  13. J Biomol Screen. 2009 Jan;14(1):49-58 [PMID: 19171920]
  14. Biol Psychiatry. 2012 Apr 15;71(8):714-24 [PMID: 22264443]
  15. Nat Rev Drug Discov. 2013 Mar;12(3):205-16 [PMID: 23411724]
  16. Curr Med Chem. 2010;17(14):1430-49 [PMID: 20166923]
  17. Mol Pharmacol. 2016 Jun;89(6):618-29 [PMID: 27009233]
  18. Cannabis Cannabinoid Res. 2016 Dec;1(1):272-280 [PMID: 28660254]
  19. Curr Opin Pharmacol. 2002 Feb;2(1):50-5 [PMID: 11786308]
  20. Methods Mol Biol. 2010;661:3-38 [PMID: 20811974]
  21. Cancer Res. 2004 Mar 15;64(6):1943-50 [PMID: 15026328]
  22. J Biol Chem. 2013 May 31;288(22):15712-24 [PMID: 23592773]
  23. Cell Mol Life Sci. 2017 Apr;74(8):1379-1390 [PMID: 27815595]
  24. Annu Rev Physiol. 2007;69:451-82 [PMID: 17037978]
  25. J Pharmacol Exp Ther. 1998 Dec;287(3):1038-47 [PMID: 9864290]
  26. Mol Pharmacol. 2005 Jun;67(6):2016-24 [PMID: 15749995]
  27. Mol Pharmacol. 2006 Mar;69(3):991-7 [PMID: 16332990]
  28. J Pharmacol Exp Ther. 2016 Aug;358(2):342-51 [PMID: 27194477]
  29. J Neurosci. 2001 Nov 15;21(22):8758-64 [PMID: 11698587]
  30. Mol Pharmacol. 1993 Sep;44(3):498-503 [PMID: 8371711]
  31. Blood. 2012 Nov 1;120(18):3741-9 [PMID: 22972984]
  32. Pharmacol Rev. 2011 Dec;63(4):1001-19 [PMID: 21873412]
  33. PLoS One. 2010 Jan 14;5(1):e8702 [PMID: 20090845]
  34. J Biol Chem. 2011 Aug 19;286(33):29166-29174 [PMID: 21719698]
  35. Behav Pharmacol. 2008 Jul;19(4):298-307 [PMID: 18622177]
  36. J Biol Chem. 2014 Sep 5;289(36):24845-62 [PMID: 25037227]
  37. Mol Pharmacol. 2000 Oct;58(4):814-20 [PMID: 10999952]
  38. Nat Commun. 2016 Nov 09;7:13416 [PMID: 27827372]
  39. Br J Pharmacol. 2012 Apr;165(8):2414-24 [PMID: 21595653]
  40. Neuropsychopharmacology. 2007 Feb;32(2):298-308 [PMID: 16760924]
  41. J Pharmacol Exp Ther. 1998 Dec;287(3):884-8 [PMID: 9864268]
  42. J Neurosci. 2014 Jun 11;34(24):8324-32 [PMID: 24920635]
  43. FASEB J. 2008 Jul;22(7):2311-22 [PMID: 18267983]
  44. J Neurochem. 1999 Aug;73(2):493-501 [PMID: 10428044]
  45. Br J Pharmacol. 2016 Feb;173(3):446-58 [PMID: 26398481]
  46. J Clin Invest. 2003 Aug;112(3):323-6 [PMID: 12897199]
  47. J Pharmacol Exp Ther. 2009 Mar;328(3):822-8 [PMID: 19106171]
  48. Mol Pharmacol. 2016 Nov;90(5):620-626 [PMID: 27338082]
  49. Biochem J. 2000 Nov 1;351 Pt 3:817-24 [PMID: 11042139]
  50. Science. 2014 Jan 3;343(6166):94-8 [PMID: 24385629]
  51. Handb Exp Pharmacol. 2015;231:261-83 [PMID: 26408164]
  52. J Neurosci. 1999 May 15;19(10):3773-80 [PMID: 10234009]
  53. Eur J Pharmacol. 2001 Nov 23;431(3):277-86 [PMID: 11730719]
  54. Nature. 2011 Jul 19;477(7366):549-55 [PMID: 21772288]
  55. Curr Med Chem. 2010;17(14):1360-81 [PMID: 20166927]
  56. Proc Natl Acad Sci U S A. 2002 Jun 11;99(12):8400-5 [PMID: 12060783]
  57. Br J Pharmacol. 2003 Oct;140(3):547-57 [PMID: 14522843]
  58. J Pharmacol Exp Ther. 2005 Sep;314(3):1195-201 [PMID: 15917400]
  59. Mol Pharmacol. 1996 May;49(5):891-6 [PMID: 8622639]
  60. J Neurosci. 1997 Jul 15;17(14):5327-33 [PMID: 9204917]
  61. J Neurosci. 1995 Oct;15(10):6552-61 [PMID: 7472417]
  62. Nature. 1993 Sep 2;365(6441):61-5 [PMID: 7689702]
  63. J Pharmacol Exp Ther. 2005 Mar;312(3):875-83 [PMID: 15525797]
  64. Br J Pharmacol. 2013 Oct;170(4):893-907 [PMID: 23937487]
  65. Neuropharmacology. 2008 Jan;54(1):36-44 [PMID: 17681354]
  66. J Biol Chem. 2000 May 26;275(21):15621-8 [PMID: 10821843]
  67. Brain. 2009 Nov;132(Pt 11):3152-64 [PMID: 19805493]
  68. Cell. 2016 Oct 20;167(3):750-762.e14 [PMID: 27768894]
  69. Br J Pharmacol. 2010 Dec;161(8):1817-34 [PMID: 20735408]
  70. Nature. 2011 Jan 13;469(7329):175-80 [PMID: 21228869]
  71. Mol Cell Neurosci. 2005 Jan;28(1):189-94 [PMID: 15607953]
  72. Biochemistry. 2011 Mar 29;50(12):2223-34 [PMID: 21306178]
  73. Trends Biochem Sci. 2011 Sep;36(9):457-69 [PMID: 21764321]
  74. Biochem Pharmacol. 1995 Jun 29;50(1):83-90 [PMID: 7605349]
  75. Mol Pharmacol. 1995 Sep;48(3):443-50 [PMID: 7565624]
  76. Science. 1992 Dec 18;258(5090):1946-9 [PMID: 1470919]
  77. J Pharmacol Exp Ther. 2000 Oct;295(1):328-36 [PMID: 10991998]
  78. Pharmacol Ther. 2002 Aug;95(2):165-74 [PMID: 12182963]
  79. Cell. 2016 Aug 11;166(4):907-919 [PMID: 27499021]
  80. J Biol Chem. 1999 Jul 16;274(29):20397-405 [PMID: 10400664]
  81. J Med Chem. 2015 Aug 13;58(15):5979-88 [PMID: 26203658]
  82. Curr Neuropharmacol. 2007;5(2):73-80 [PMID: 18615177]
  83. J Biol Chem. 2005 Sep 30;280(39):33426-34 [PMID: 16046413]
  84. Mol Endocrinol. 2010 Jan;24(1):161-70 [PMID: 19901198]
  85. Nature. 2016 Nov 24;539(7630):555-559 [PMID: 27828947]
  86. Biochim Biophys Acta. 2011 Aug;1813(8):1554-60 [PMID: 21640764]
  87. Cell Mol Life Sci. 2016 Dec;73(23):4449-4470 [PMID: 27402121]
  88. J Pharmacol Exp Ther. 2013 Mar;344(3):708-17 [PMID: 23300227]
  89. Nature. 2016 Dec 22;540(7634):602-606 [PMID: 27851727]
  90. Mol Cell Endocrinol. 2013 Jun 15;372(1-2):116-27 [PMID: 23541635]
  91. Eur J Pharmacol. 2008 Feb 26;581(1-2):19-29 [PMID: 18162180]
  92. J Neurophysiol. 2009 Aug;102(2):1160-71 [PMID: 19494194]
  93. J Biol Chem. 2012 Apr 6;287(15):12070-82 [PMID: 22343625]
  94. Eur J Pharmacol. 1999 Jun 25;374(3):445-55 [PMID: 10422789]
  95. Mol Pain. 2009 Mar 10;5:11 [PMID: 19284549]
  96. Neuropharmacology. 2016 Aug;107:201-214 [PMID: 26970018]
  97. Proc Natl Acad Sci U S A. 1992 May 1;89(9):3825-9 [PMID: 1315042]
  98. Proc Natl Acad Sci U S A. 1995 Aug 1;92(16):7242-6 [PMID: 7638174]
  99. Mol Pharmacol. 1999 Dec;56(6):1362-9 [PMID: 10570066]
  100. FEBS Lett. 2007 Oct 16;581(25):5009-16 [PMID: 17910957]
  101. Nat Neurosci. 2012 Mar 04;15(4):558-64 [PMID: 22388959]
  102. J Med Chem. 2003 Nov 20;46(24):5139-52 [PMID: 14613317]
  103. Mol Pharmacol. 1999 Sep;56(3):611-8 [PMID: 10462549]
  104. Chem Biol. 2011 Aug 26;18(8):1053-64 [PMID: 21867920]
  105. Biochem Pharmacol. 2010 Oct 1;80(7):1050-62 [PMID: 20599795]
  106. J Pharmacol Exp Ther. 1988 Mar;244(3):1157-63 [PMID: 2855242]
  107. Neuron. 2016 May 18;90(4):795-809 [PMID: 27133464]
  108. Brain Res Mol Brain Res. 2004 Jan 5;120(2):138-44 [PMID: 14741403]
  109. J Biol Chem. 2006 Sep 29;281(39):29085-95 [PMID: 16864584]
  110. Mol Pharmacol. 2013 Feb;83(2):322-38 [PMID: 23160940]
  111. Neurosignals. 2003 Jan-Feb;12(1):39-44 [PMID: 12624527]
  112. J Biol Chem. 2003 Dec 5;278(49):48973-80 [PMID: 14517212]
  113. Nature. 2016 Sep 8;537(7619):185-190 [PMID: 27533032]
  114. Biochem Biophys Res Commun. 1995 Oct 4;215(1):89-97 [PMID: 7575630]
  115. J Biol Chem. 2013 Apr 5;288(14):9790-9800 [PMID: 23449980]
  116. Brain Res. 2003 Aug 8;980(2):197-205 [PMID: 12867259]
  117. Eur J Biochem. 1996 May 1;237(3):704-11 [PMID: 8647116]
  118. J Pharmacol Exp Ther. 2005 Nov;315(2):828-38 [PMID: 16081674]
  119. J Biol Chem. 2004 Aug 20;279(34):36013-21 [PMID: 15210689]
  120. J Neurosci. 2011 May 11;31(19):7122-30 [PMID: 21562274]
  121. Mol Pharmacol. 2004 Apr;65(4):999-1007 [PMID: 15044630]
  122. Nat Commun. 2016 Feb 24;7:10842 [PMID: 26905976]
  123. Mol Pharmacol. 2015 Aug;88(2):368-79 [PMID: 26044547]
  124. FASEB J. 2007 Mar;21(3):802-11 [PMID: 17197383]
  125. J Neurochem. 2001 May;77(3):957-60 [PMID: 11331425]
  126. Mol Pharmacol. 2002 Dec;62(6):1385-92 [PMID: 12435806]
  127. Br J Pharmacol. 2012 Mar;165(6):1773-1788 [PMID: 21951063]
  128. Pharmacol Res. 2016 Sep;111:434-441 [PMID: 27378564]
  129. Nat Commun. 2017 Jan 03;8:13958 [PMID: 28045021]
  130. Br J Pharmacol. 2004 Nov;143(6):685-96 [PMID: 15504746]
  131. Nature. 1990 Aug 9;346(6284):561-4 [PMID: 2165569]
  132. J Neurochem. 2008 Jul;106(1):70-82 [PMID: 18331587]
  133. Cell Signal. 2003 Sep;15(9):851-9 [PMID: 12834810]
Journal Article Review
Article has an altmetric score of 24

Word Cloud

Created with Highcharts 10.0.0CBpathwaysreceptorsignalingactivatedifferentcannabinoidagonistcancascadeseffectsreceptorsevidencebiasactssinglenumerousRecentstudiessuggestedligandsdifferentiallystabilizinglimitedrangeconformationsturnpreferentiallydrivedownstreamconcepttermed"biasedsignaling"representsexcitingtherapeuticopportunitytargetspecificelicitdesiredavoidingundesiredmediatedmultipleemergingwithinreviewwillsummarizecurrentbiasedsubtypesCannabinoidReceptorSignalingBiasGprotein-coupledfunctionalselectivity

Similar Articles

Cited By